Biomicroscopic Findings and Management of Anterior Stromal Necrosis After Long-term Implantation of Intacs.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
12 2020
Historique:
received: 07 05 2020
revised: 17 07 2020
accepted: 20 07 2020
pubmed: 31 7 2020
medline: 23 12 2020
entrez: 31 7 2020
Statut: ppublish

Résumé

We sought to evaluate the visual, refractive, and biomicroscopic findings pre- and posttreatment of observed anterior stromal necrosis (ASN) after long-term Intacs intracorneal ring segment (ICRS) implantation. Consecutive interventional case series. All consecutive patients implanted with Intacs ICRS at a single center by 1 of the authors between October 2006 and October 2011 with a minimum follow-up time of 5 years were included. All Intacs were implanted using the Prolate system console and instrumentation from Addition Technology Inc (Chicago, Illinois, USA). The slit lamp, refractive, and visual findings and the management of those patients are described in detail. The primary outcome measures included the size of the epithelial defect overlying the Intacs body, the intended implantation depth measured by high-magnification slit lamp photography, and the management of the cases described in detail. The percentage of eyes with ASN out of those that reached the 5-year follow-up is reported. One hundred twenty-seven eyes (84 patients) were implanted with 215 ICRSs during the study period, and 77.16% (98/127) eyes had a follow-up of ≥5 years, out of which 9 eyes (7 patients) had ASN corresponding to at least 9.18% (95% confidence interval 4.29%-16.72%). The mean ± standard deviation time between implantation and ASN diagnosis was 10.5 ± 1.3 years. After 5 years of implantation, INTACS-treated eyes could present with an ASN over the ICRS body. Longer-term follow-up of patients implanted with INTACS is important to monitor if this complication keeps occurring over time.

Identifiants

pubmed: 32730912
pii: S0002-9394(20)30390-1
doi: 10.1016/j.ajo.2020.07.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

170-176

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Juan-Carlos Abad (JC)

Private Practice, Clinica Oftalmologica de Antioquia, CLOFAN, Medellín, Colombia. Electronic address: jcabad@gmail.com.

Isabel C Gomez (IC)

Department of Ophthalmology, Universidad Pontificia Bolivariana, Medellín, Colombia; Research Department at Oftalmosalud Instituto de Ojos, Lima, Peru.

Maria A Henriquez (MA)

Research Department at Oftalmosalud Instituto de Ojos, Lima, Peru.

Jorge H Donado (JH)

Department of Medicine, Universidad Pontificia Bolivariana, Medellín, Colombia; Department of Clinical Epidemiology, Hospital Pablo Tobón Uribe, Medellín, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH